Acumen Pharmaceuticals, Inc.ABOSNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+54.3%
5Y CAGR+71.6%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+54.3%/yr
Annual compound
5Y CAGR
+71.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
14.9x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$118.93M+26.8%
2024$93.80M+121.7%
2023$42.32M+30.8%
2022$32.36M+163.0%
2021$12.30M+53.9%
2020$8.00M-6.8%
2019$8.58M-